Alacrimia-choreoathetosis-liver dysfunction syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:404454OMIM:615273E77.8
Who is this for?
Show terms as
2Active trials2Specialists8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Alacrimia-choreoathetosis-liver dysfunction syndrome is an extremely rare genetic disorder that affects multiple body systems. The name describes its three main features: alacrimia (the inability to produce tears), choreoathetosis (involuntary writhing and jerky movements), and liver dysfunction (problems with how the liver works). This condition falls under a group of disorders related to abnormal processing of certain sugars attached to proteins, known as congenital disorders of glycosylation. Children with this syndrome typically show signs early in life. The lack of tears can lead to dry, irritated eyes and increase the risk of eye infections and damage. The movement problems (choreoathetosis) can make it difficult to control the arms, legs, and body, affecting walking, feeding, and daily activities. Liver dysfunction can range from mildly abnormal liver blood tests to more significant liver disease. Because this condition is so rare, there is no specific cure. Treatment focuses on managing each symptom individually. Eye drops or artificial tears help protect the eyes. Medications may be used to help control involuntary movements. Liver function is monitored regularly, and supportive care is provided as needed. A team of specialists working together is important for the best possible care.

Also known as:

Key symptoms:

Inability to produce tears (dry eyes)Involuntary writhing or jerky body movementsLiver problems or abnormal liver function testsDifficulty with coordination and balanceDevelopmental delayDifficulty feedingLow muscle tone in infancyElevated liver enzymes in blood testsEye irritation or frequent eye infectionsDifficulty walking or delayed motor milestonesSpeech difficultiesIntellectual disability

Clinical phenotype terms (50)— hover any for plain English
Decreased CSF homovanillic acid concentrationHP:0003785HypotriglyceridemiaHP:0012153Abnormal myelinationHP:0012447Chronic constipationHP:0012450Decreased CSF 5-hydroxyindolacetic acid concentrationHP:0025455Decreased CSF protein concentrationHP:0025457Decreased CSF albumin concentrationHP:0025458Corneal neovascularizationHP:0011496LagophthalmosHP:0030001Decreased CSF biopterin levelHP:0040209Facial hypotoniaHP:0000297Corneal scarringHP:0000559Congenital hip dislocationHP:0001374
Inheritance

Autosomal recessive

Passed on when both parents carry the same gene change; often skips generations

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗OMIM ↗NORD ↗

FDA & Trial Timeline

2 events
Jan 2025A Study of GlcNAc on Tear Production in NGLY1-CDDG

Eva Morava-Kozicz — PHASE2

TrialACTIVE NOT RECRUITING
Feb 2024Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

Grace Science, LLC — PHASE1, PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Alacrimia-choreoathetosis-liver dysfunction syndrome.

2 clinical trialsare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

2 recruitingView all trials with filters →
Phase 21 trial
A Study of GlcNAc on Tear Production in NGLY1-CDDG
Phase 2
Active
PI: Eva Morava-Kozicz, MD, PhD (Icahn School of Medicine at Mount Sinai) · Sites: Philadelphia, Pennsylvania; Seattle, Washington · Age: 160 yrs

Specialists

2 foundView all specialists →
EP
Eva Morava-Kozicz, MD, PhD
ROCHESTER, MN
Specialist
PI on 7 active trials
BM
Bernhard Suter, MD
HOUSTON, TX
Specialist
PI on 1 active trial

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Alacrimia-choreoathetosis-liver dysfunction syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Alacrimia-choreoathetosis-liver dysfunction syndromeForum →

No community posts yet. Be the first to share your experience with Alacrimia-choreoathetosis-liver dysfunction syndrome.

Start the conversation →

Latest news about Alacrimia-choreoathetosis-liver dysfunction syndrome

Disease timeline:

New recruiting trial: Clinical and Basic Investigations Into Congenital Disorders of Glycosylation

A new clinical trial is recruiting patients for Alacrimia-choreoathetosis-liver dysfunction syndrome

New recruiting trial: Safety and Efficacy of GS-100 Gene Therapy in Patients With NGLY1 Deficiency

A new clinical trial is recruiting patients for Alacrimia-choreoathetosis-liver dysfunction syndrome

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Questions for your doctor

Bring these to your next appointment

  • Q1.How severe is my child's liver involvement, and how often should liver function be monitored?,What medications or therapies can help control the involuntary movements?,How can we best protect my child's eyes from damage due to lack of tears?,Are there any clinical trials or experimental treatments available for this condition?,What developmental therapies should we start, and how often?,Should we consider genetic counseling for our family regarding future pregnancies?,What emergency signs should we watch for at home?

Common questions about Alacrimia-choreoathetosis-liver dysfunction syndrome

What is Alacrimia-choreoathetosis-liver dysfunction syndrome?

Alacrimia-choreoathetosis-liver dysfunction syndrome is an extremely rare genetic disorder that affects multiple body systems. The name describes its three main features: alacrimia (the inability to produce tears), choreoathetosis (involuntary writhing and jerky movements), and liver dysfunction (problems with how the liver works). This condition falls under a group of disorders related to abnormal processing of certain sugars attached to proteins, known as congenital disorders of glycosylation. Children with this syndrome typically show signs early in life. The lack of tears can lead to dry,

How is Alacrimia-choreoathetosis-liver dysfunction syndrome inherited?

Alacrimia-choreoathetosis-liver dysfunction syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Alacrimia-choreoathetosis-liver dysfunction syndrome typically begin?

Typical onset of Alacrimia-choreoathetosis-liver dysfunction syndrome is infantile. Age of onset can vary across affected individuals.

Are there clinical trials for Alacrimia-choreoathetosis-liver dysfunction syndrome?

Yes — 2 recruiting clinical trials are currently listed for Alacrimia-choreoathetosis-liver dysfunction syndrome on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Alacrimia-choreoathetosis-liver dysfunction syndrome?

2 specialists and care centers treating Alacrimia-choreoathetosis-liver dysfunction syndrome are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.